Formulations of lixivaptan, and methods of using the same, are provided for the treatment of polycystic disease.

A method for treating, attenuating or inhibiting an infection and/or disease associated with a SARS virus in a subject is provided that includes administering a pharmaceutical composition to the subject. The composition includes an organosilicone carrier with one or more active substances that block and/or inhibit an ACE2 receptor in a host cell of the subject, the spike protein of a SARS virus and/or internal components of a virion of the SARS virus.

Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.

A nutritional product for improving performance during physical activity and a method of using the nutritional product to improve performance during activity. The nutritional product contains Rhodiola root extract, French pine extract, Pulsatilla vulgaris extract, ginger extract, yohimbe extract, Ginseng extract, Coleus forskohlii extract, vitamin B12, red beet extract, L-Arginine NO3, tongkat ali, a combination of Fenugreek fenugreek A and Fenugreek fenugreek B, and Tribulus terrestris extract. Also described are methods for improving a user's physical activity performance employing the nutritional products.

Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Systems and methods for releasing a material into an environment. The material may be encapsulated in a receptacle or otherwise packaged for movement into the environment. The receptacle with the material inside is introduced into the environment. A triggering causes release of the material from the receptacle into the environment.

The present disclosure provides techniques for producing whey protein nano-emulsions from cannabis extracts. An emulsion prepared using an embodiment of a method of the invention can be subject to further processing with which to convert the emulsion (or a component thereof) into one or more consumables.

The present invention discloses compositions comprising CBD and several herbal extract and use thereof in treatment of mental disorders such as Attention Deficit Hyperactivity disorder (ADHD) and Post Traumatic Stress Disorder (PTSD).

Antihypertensive agents which are crystalline having a general plate shape may be difficult to formulate as they often do not exhibit good flowability properties. Addition of spray-dried riboflavin surprisingly improves flowability of these agents.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.